Biogen discovers, develops, and markets pharmaceutical therapies across the United States, Europe, and Asia, with a portfolio spanning neurological conditions, autoimmune diseases, and oncology. The company's products include treatments for multiple sclerosis and spinal muscular atrophy, biosimilar versions of major immunology drugs, and oncology therapies targeting blood cancers and lymphomas, along with recent approvals for Alzheimer's disease and postpartum depression. Biogen maintains numerous research partnerships and licensing agreements with biotech firms and pharmaceutical companies to advance pipeline candidates in neurology and other therapeutic areas.

entry readiness 12 · NOT READY · exit proximity 0

Value area 185.79–215.51 · 4% of 120d volume overhead · clean runway